Article Text

Download PDFPDF
#1338 Unveiling the clinical impact of tumor-based next-generation sequencing in ovarian cancer: insights from real-world data
  1. Luisa Sánchez-Lorenzo and
  2. Antonio González-Martín
  1. Clinica Universidad de Navarra, Navarra, Spain


Introduction/Background Tumor-based next-generation sequencing (NGS) has been pivotal in unraveling the intricate molecular landscapes characterizing distinct subtypes of ovarian cancer. Today, NGS stands at the forefront of tailoring precise treatments for ovarian cancer patients. This study aims to assess the clinical implications of integrating tumor-based NGS in ovarian cancer treatment by examining how these findings shape everyday clinical approaches and to analyze the survival benefits observed in patients undergoing targeted therapy tailored by these test outcomes, drawing insights from real-world data.

Methodology At Clínica Universidad de Navarra across our two locations in Pamplona and Madrid, we conducted a retrospective study involving individuals diagnosed with ovarian cancer who had undergone at least one NGS panel test between September 2017 and September 2023 Comprehensive genetic, clinical and demographic data were gathered from patient records. Formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens were analyzed by Oncomine™ Comprehensive Assay Plus, Oncomine™ Comprehensive Assay v3, or FoundationOne CDx test. Multivariate COX regression and clustering analyses were performed to identify patterns of genetic alterations associated with progression-free survival.

Results Data from 202 cases of ovarian cancer over 5 years were collected. One or more genetic alterations were detected in 201/202 (99.5%). Among these, in 5/202 (2.47%), multiple NGS platforms were used throughout the disease course, highlighting clonal evolution during disease progression. The combinations of genetic alterations, identified through multivariate Cox regression and clustering analyses and corresponding to outcomes, will be showcased in final results. We will also include data concerning patients who did or did not, receive a matching drug for those with at least one reported druggable alteration. Moreover, the final results will encompass the observed survival benefits in patients undergoing targeted therapy based on these tests.

Conclusion Tumor-based NGS frequently provides clinically significant information. It holds the potential to reveal specific therapeutic targets and contribute to clinical decision-making

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.